Clinical Research, Pharma & Healthcare FinancingAnbogen Gets FDA Nod for Phase 1/2 Colorectal Cancer TrialPR NewswireAugust 4, 2025August 19, 2025 by PR NewswireAugust 4, 2025August 19, 2025058 Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation...
